PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2020-05-12 07:22:44
Oslo, Norway, May 12th, 2020 Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, announces its first quarter results for 2020.
Michael Engsig, Chief Executive Officer at Vaccibody, comments:
“The First quarter 2020 was important for Vaccibody, with the expansion of the strategic focus into infectious diseases. Further, attention has been on operational execution, safety and mitigation in the light of Covid-19.”
Highlights 1Q 2020 and subsequent events
Vaccibody AS is registered on the NOTC-list as of January 27, 2020
Vaccibody AS announces the expansion of its strategic focus to include Infectious Diseases
Vaccibody AS announces the appointment of Gunnstein Norheim, Ph.D., as its new Director Infectious Diseases leading this new initiative
VB10.NEO: VB N-01 - As per 31 March, 38 patients have been enrolled in the study
VB10.16: VB C-02 The majority of countries have approved the study
Financial review per 1Q 2020
Income statement - The net result for 1Q20 was a net loss of NOK 31.4 million compared to a NOK 19.9 million loss in 1Q19
Total operating expenses amounted to NOK 43.5 million in 1Q20 compared to NOK 22.9 million in 1Q19
Net financial income and expenses increased to NOK 10.8 million in 1Q20 compared to NOK 0.1 million in 1Q19
Cash position of NOK 254.6 million compared to NOK 341.1 million at March 31, 2019
Outlook
The primary clinical objectives are to:
VB10.NEO: VB N-01 - complete the enrolment of patients including the basket arm 5B which investigates VB10.NEO in combination with Nektar Therapeutics bempegaldesleukin (NKTR-214)
VB10.16: VB C-02 - Initiate enrolment in the trial investigating VB10.16 in combination with atezolizumab in patients with advanced or recurrent cervical cancer
Infectious Disease area - Vaccibody will lay out its strategy for the area during the course of 2020
Please find the full 1Q 2020 Report on the Companys website in the Investors section.
Contact:
CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
E: mengsig@vaccibody.com